Atara Biotherapeutics (ATRA) Stock Statistics & Valuation Metrics

Atara Biotherapeutics has a market cap or net worth of CHF69.80M. The enterprise value is ―.

Atara Biotherapeutics has ― shares outstanding. The number of shares has decreased by -2.65% in one year.

Atara Biotherapeutics’s return on equity (ROE) is 0.88 and return on invested capital (ROIC) is -3538.01%.

The current PE Ratio of Atara Biotherapeutics is ―. Atara Biotherapeutics’s PEG ratio is 0.01.

In the last 12 months, Atara Biotherapeutics had revenue of 128.94M and earned -85.40M in profits. Earnings per share was -11.41.

In the last 12 months, operating cash flow was -63.92M and capital expenditures -90.00K, giving a free cash flow of -64.01M billion.

Atara Biotherapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Atara Biotherapeutics upcoming earnings date is Nov 18, 2025, TBA (Confirmed).

Atara Biotherapeutics as a current ratio of 0.48, with Debt / Equity ratio of -44.02%

In the past 12 months, Atara Biotherapeutics has paid -12.00K in taxes.

Atara Biotherapeutics EV to EBITDA ratio is -1.56, with an EV/FCF ratio of -1.72.

Atara Biotherapeutics has CHF22.32M in cash and marketable securities with CHF15.43M in debt, giving a net cash position of CHF6.90M billion.

Gross margin is 81.24%, with operating margin of -64.71%, and net profit margin of -66.23%.

The average price target for Atara Biotherapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―